Unity Biotechnology Inc (STU:9U90)
€ 1.308 -0.008 (-0.61%) Market Cap: 22.57 Mil Enterprise Value: 9.93 Mil PE Ratio: 0 PB Ratio: 0.98 GF Score: 30/100

UNITY Biotechnology Inc To Discuss The Most Recent UBX1325 Clinical Data Call Transcript

Apr 24, 2023 / 12:00PM GMT
Unidentified Company Representative

Good morning, and welcome to the Unity Biotechnology conference call and webcast. At this time, all attendees are in a listen-only mode. A question-and-answer session will follow the formal presentations. As a reminder, this call is being recorded and a replay will be made available on the Unity website following the conclusion of the event.

I'd now like to turn the call over to Lynne Sullivan, Chief Financial Officer of Unity Biotechnology. Please go ahead, Lynne.

Lynne Sullivan
Unity Biotechnology, Inc. - CFO

Thanks, [Tara]. Good morning and thank you for joining Unity Biotechnology's conference call to review the 48-week data from our Phase 2 BEHOLD Study of UBX1325 in patients with DME.

With me on today's call is Anirvan Ghosh, the CEO of Unity Biotechnology; Jamie Dananberg, our Chief Medical Officer; Mike Sapieha, our Chief Scientist; and myself, Lynne Sullivan, the Chief Financial Officer. We are fortunate to have Dr. Robert Bhisitkul, Professor of Ophthalmology and Director of the Retina Fellowship at the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot